Be Biopharma is developing cell therapies by engineering B cells to churn out therapeutic proteins with an initial focus on cancer and rare disease. The company’s Series B financing comes as competitors in the space also make progress with their engineered B cell therapies.
Move over, A: B is taking the lead now, with Be Biopharma closing out a $130 million financing round backed by several industry leaders that will fuel its engineered B cells platform.